San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.

iBio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and ...

iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...

In consideration for these rights, iBio has agreed to pay AstralBio an upfront license fee of $750,000, to be paid in shares of iBio’s common stock. Additionally, milestone payments of up to $28 ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for ...

Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio ...

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and ...